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Abstract
Background Real-world evidence for the safety of using antithrombotics in older people with multimorbidity is limited. We
investigated the risks of gastrointestinal bleeding (GI-bleeding) and intracranial (IC-bleeding) associated with antithrombotics
either as monotherapy, dual antiplatelet therapy (DAPT) or as triple therapy (TT) [DAPT plus anticoagulant] in older individuals
aged 65 years and above.
Methods We identified all individuals, 65 years and above, who had a first-time event of either IC- or GI-bleeding event from the
hospital discharge data. We employed a case-crossover design and conditional logistic regression analyses to estimate the
adjusted relative risks (ARR) of bleeding.
Results We found 66,500 individuals with at least one event of IC- or GI-bleeding between 01/01/2005 and 31/12/2014. DAPT
use was associated with an increased risk relative to non-use of any antithrombotics in IC-bleeding (ARR = 3.13, 95%CI = [2.64,
3.72]) and GI-bleeding (ARR = 1.34, 95% CI = [1.14, 1.57]). The increased bleeding risk relative to non-use of any
antithrombotics was highest with TT use (IC-bleeding, ARR = 17.28, 95% CI = [6.69, 44.61]; GI-bleeding, ARR = 4.85, 95%
CI = [1.51, 15.57]).
Conclusions Using population-level data, we were able to obtain estimates on the bleeding risks associated with antithrombotic
agents in older people often excluded from clinical trials because of either age or comorbidities.
Keywords Antithrombotics . Anticoagulants . Aspirin .Warfarin . Bleeding . Atrial fibrillation
Introduction
Dual antiplatelet therapy (DAPT) combines aspirin and
clopidogrel, ticagrelor or other antiplatelet drugs, and is
recommended to reduce the risk of thrombotic events in patients
with acute coronary syndromes (ACS) or for individuals under-
going percutaneous coronary interventions (PCI) [1–3]. In an
individual with a diagnosis of atrial fibrillation (AF), after ACS
or PCI, an anticoagulant drug, typically warfarin or one of the
direct oral anticoagulants, is used concurrently with DAPT; this
combination treatment is typically known as Btriple therapy^
(TT) [4, 5].
Studies that have examined the risk of bleeding using
DAPT and TT regimens have reported mixed findings.
Some studies have shown that the concomitant use of warfarin
with DAPT increases the risk of bleeding [6–8]. However,
others reported no association of an increased risk of bleeding
[9, 10]. Older people prescribed DAPT or TT because of a
percutaneous intervention and AF are excluded from clinical
trials because of comorbidities or extremes of age. Hence, in
the absence of clear guidance from clinical trials and head-to-
head comparisons, there remains an ongoing research gap on
the bleeding risks associated with antithrombotics in older
people with multimorbidity. We need reliable population-
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level evidence for the safety of using antiplatelet, anticoagu-
lants as either monotherapy, DAPT or TT treatments particu-
larly in older people within the context of varying doses and
multimorbidity. In this study, we analysed New Zealand’s
pharmaceutical information database (Pharms) and national
minimum data set (NMDS), to examine the association of
the risks of intracranial bleeding (IC-bleeding) and gastroin-
testinal bleeding (GI-bleeding) with concomitant use of anti-
coagulants and antiplatelet either as monotherapy, DAPT or
TT regimens in older individuals.
Methods
The Human Ethics Research Committee, University of Otago
approved the study (approval number HD 16/077).
Source of Data
The New Zealand Ministry of Health maintains national col-
lections of prescription use and hospital discharges. Individual
records in these national collections include a unique 7-digit
alphanumeric identifier, known as the National Health Index
(NHI) identifier. The NHI is encrypted in all datasets, but there
is only one encrypted version of each NHI that is never
changed. Therefore, we were able to link new data with
datasets previously extracted. The pharmaceutical information
database (Pharms) includes a record of all prescription claims
made by community pharmacists funded by Pharmaceutical
Management Agency (PHARMAC). The pharmaceutical col-
lections contain patient demographic information including
age, sex, ethnicity, deprivation scores and detailed information
about drugs dispensed including drug name, dispensing date,
formulation type, administration route, dose, weight, frequen-
cy, quantity prescribed and quantity dispensed. The National
Minimum Dataset (NMDS) is a collection of hospital dis-
charges for inpatients and day patients. The coding of patients’
diagnoses is in accordance with the International
Classification of Diseases and Related health problems tenth
revision, Australian Modification (ICD-10-AM).
Study Design
We identified all individuals, 65 and above with a first-time
event of either IC- or GI-bleeding, between 01/01/2005 and
31/12/2014. The index date was the first-time event date for
the individual with IC- or GI-bleeding after 01/01/2005. We
identified bleeding events using the ICD-10-AM (sixth revi-
sion)-coded diagnoses for GI- or IC-bleeding (Supplementary
Table 1) from the NMDS. In the spirit of Poulson and col-
leagues [11], we considered the code for traumatic subdural
haemorrhage (S065) to capture majority of the SDH cases.
In this study, we considered only drugs funded by
Pharmaceutical Management Agency (PHARMAC) including
prescriptions of anticoagulants (warfarin and dabigatran), anti-
platelet (dipyridamole, clopidogrel), aspirin and effect-
modifiers (Supplementary Table 2). PHARMAC subsided
dabigatran from July 2011. In this study, effect-modifiers are
drugs that modify the risk of cardiovascular events and haem-
orrhage. The main effect-modifiers considered in this study
included statins (which lowers the risk of a cardiovascular
event), selective serotonin receptor inhibitors (SSRIs) (which
are associatedwith increased risk of bleeding) and non-steroidal
anti-inflammatory drugs (NSAIDs) (which increase both
cardiovascular risk and risk of GI-bleeding) (Supplementary
Table 2). We did not consider over-the-counter drugs for this
study. We analysed the CSV-formatted datasets using a com-
puter program written in R. Figure 1 depicts the process of case
selection as shown. We partitioned the final dataset into an IC-
bleeding cohort and a GI-bleeding cohort.
Statistical Analysis
Analyses were conducted using R version 3.2.4 Revised (2016-
03-16 r7033). We used a case-crossover design [12, 13] to ex-
amine the population-level association of IC- or GI-bleeding
risks associated with concomitant use of anticoagulants, anti-
platelet and aspirin (Supplementary Table 2). Two 7-day obser-
vation periods with each preceded by a 35-day wash-out period
were defined over an 84-day study period (Fig. 1). The case
period was the observation period 1–7 days before the index date
(day of event). The control period is the observation period 43–
49 days before the index date. From the prescription data, we can
work out the duration of each prescription by dividing the total
dose supplied by the daily dose. Together with the prescription
dates, we can determine whether an individual has access to
aspirin only (aspirin monotherapy), anticoagulant (AC) only (an-
ticoagulant monotherapy-either warfarin or dabigatran), anti-
platelet (AP) only (antiplatelet monotherapy-either dipyridamole
or clopidogrel), AP and AC, aspirin and AC, aspirin and AP
(DAPT), all three (TT) or none within the case period and the
control period. The prescription data do not explicitly indicate
whether a particular drug-therapy (i.e. TT, DAPT,AP/AC/aspirin
monotherapies or other double-therapies involving AP, AC or
aspirin) is taken. Hence, we determined the drug therapies that
an individual might be using within an observation period based
on the classes of drugs accessible (AP, AC, aspirin or some
combinations of them) with the observation period of interest.
Table 1 shows the definitions for antithrombotics as monothera-
py, DAPT and TT.
Time-invariant or slow-changing confounding variables
are automatically balanced in a case-crossover design, even
if they are unknown [14]. However, the influence of time-
variant confounding variables has to be accounted to obtain
precise estimates of bleeding risks following antithrombotic
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exposure. In this study, concomitant use of other drugs that
change the risks of cardiovascular events and haemorrhage
(i.e. the effect-modifiers) are obvious time-varying confound-
ing variables. From the case-crossover design, for each, we
computed the combination of aspirin, AC and AP used over
an observation period; and whether or not a bleeding event
occurred at the end of the same observation period. Using
conditional logistic regression (CLR), we were able to esti-
mate the changed risk of IC- or GI-bleeding associated with
monotherapies of aspirin, AC or AP, DAPT and TT as well as
other double therapies involving AP, AC or aspirin, relative to
non-use. We report the changed risks as relative risks (RR).
CLR accounts for the between-individual variation of health
characteristics when estimating the changed risk with drug
exposure, and thus mitigates confounding. We used multivar-
iable CLR to adjust for the influence of the concomitant use of
effect-modifiers (Supplementary Table 2) to calculate the ad-
justed relative risks (ARR).
Results
We found 70,800 individuals with at least one diagnosis of IC-
or GI-bleeding between 01/01/2005 and 31/12/2014 (Fig. 2).
We excluded 1079 individuals as they did not receive any
prescription of aspirin, AC, AP or any effect-modifiers of
interests, and 3221 of them were further excluded because at
least one IC- or GI-bleed had occurred within 12 months from
01/01/2005, implying a potentially less reliable date of first-
time bleeding (Fig. 2). Amongst the 66,500 individuals re-
maining, 19,600 of them had IC-bleeding on the index date
and received at least one prescription of AC, AP or aspirin
84 days before the event. These individuals were categorised
as the IC-bleeding cohort. Furthermore, 15,219 of them had
GI-bleeding on the index date and received at least one pre-
scription of the same drugs 84 days before the event, and these
individuals formed the GI-bleeding cohort. The characteristics
of the study cohorts are shown in Fig. 3. In both study cohorts,
males were slightly more than females, and a vast majority of
them are NZ-Europeans and only a small proportion of them
are Māori (Fig. 3).
Figure 4 displays results of the adjusted relative risk (ARR)
analysis. Relative to non-use of any antithrombotics, aspirin and
antiplatelet monotherapies are associated with a mild increased
risk of incident IC-bleeding (aspirin, ARR = 1.38, 95%
CI = [1.31, 1.47], AP, ARR= 1.07, 95% CI = [0.98, 1.18]), and
no association was found with incident GI-bleeding (aspirin,
ARR = 0.84, 95% CI = [0.79, 0.89], AP, ARR = 0.97, 95%
Case period
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Wash-out period
(35 days)
Prescripon 
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Fig. 1 The case-crossover design
and the source of data
Table 1 Detailing the definitions of monotherapies and combined therapies
Aspirin
exposure
AC-exposure AP-exposure
Warfarin Dabigatran Clopidogrel Dipyridamole
Aspirin monotherapy
AC monotherapy
AP monotherapy
AP and AC
Aspirin and AC
DAPT
TT
AC-exposure means exposure to warfarin only or dabigatran. AP-exposure means exposure to either clopidogrel or dipyridamole
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CI = [0.87, 1.08]). However, concomitant use of AP and aspirin
as DAPT increases the risk of incident IC-bleeding three times
comparing to non-use of any antithrombotics (ARR= 3.13, 95%
CI = [2.64, 3.72]), and is associated with incident GI-bleeding
(ARR= 1.34, 95% CI = [1.14, 1.57]).
The use of anticoagulant monotherapy significantly in-
creases the risk of IC-bleeding (ARR = 8.33, 95%
CI = [6.72, 10.33]) relative to non-use of any antithrombotics,
and moderately increases the risk of GI-bleeding (ARR =
1.71, 95% CI = [1.38, 2.13]). Despite the wide 95% confi-
dence intervals, the risk of incident IC-bleeding further in-
creases when AC is co-used with aspirin (ARR = 11.79,
95% CI = [9.68, 14.36]) or AP (ARR = 15.89, 95%
CI = [6.41, 39.35]) or both aspirin and AP as TT (ARR =
17.28, 95% CI = [6.69, 44.61]) relative to non-use of any
antithrombotics. For incident GI-bleeding, the risk further in-
creases when AC is co-used with aspirin (ARR = 1.79, 95%
CI = [1.30, 2.46]) or AP (ARR = 6.36, 95% CI = [2.24,
18.03]) or in TT with both aspirin and AP (ARR = 4.85,
95% CI = [1.51, 15.57]) relative to non-use of any
antithrombotics.
Overall, the relative risk analysis (Fig. 4) shows that with or
without adjusting for concomitant uses of effect-modifiers,
concomitant prescribing of aspirin, AP or AC is associated
Starng populaon: 
70800 individuals (65yr +) with 
at least one diagnosis of IC-
bleeding or GI-bleeding 
between 01/01/2005 and 
12/31/2014 based on NMDS.
69721 individuals have at least 
one prescripon of warfarin, 
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dipyrimadole, aspirin or eﬀect-
modiﬁers between 01/01/2005 
and 12/31/2015 based on 
PHARMS.
66500 individuals have at least 
one diagnosis IC or GI-bleeding 
between 01/01/2005 and 
12/31/2014, but not within 12 or 
more months before the ﬁrst-
me bleeding aer 01/01/2005.
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without any prescripons 
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Fig. 2 The process of case
selection. The length of the study
period is 84 days based on Fig. 1
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with larger increases in incident IC or GI-bleeding, compared
to using them as monotherapies.
Discussion
This national study found that the use of DAPT and TT regi-
mens is associated with a higher risk of both IC- and GI-
bleeding than non-use. Importantly, individuals receiving
DAPT (i.e. dual therapy with aspirin and antiplatelet) had a
two–three times higher risk of IC-bleeding than individuals on
monotherapy, consistent with a cumulative pharmacodynamic
effect. A similar effect size of higher bleeding risk was report-
ed in an observational registry-based study conducted in
Denmark in individuals (age 73.7 (SD = 12.3)) diagnosed
with AF [6]. There is clinical ambiguity surrounding the ap-
propriateness of using combination antithrombotics particu-
larly in individuals diagnosed with AF. Observational studies
have unequivocally shown that the combination of warfarin
and aspirin is associated with serious bleeding complications;
however, the sample sizes in these studies were relatively
small compared to our national study. A meta-analysis led
by Dentali et al. found an increased risk of bleeding associated
with the combination of warfarin and aspirin compared with
either, but the heterogeneity of study designs and the variabil-
ity in the population included limits their external validity.
Findings from meta-analyses are not reflective of the real risk
posed in high-risk populations such as the elderly given that
clinical trials routinely exclude older individuals using DAPT
including those with a history of GI ulcers and those taking
concomitant drugs.
Interestingly, our study also found an increased risk of IC-
bleeding associated with aspirin alone. A systematic review of
observational studies found that the overall pooled estimate of
the relative risk of IC-bleeding with low-dose aspirin was 1.4
(95% CI, 1.2–1.7). In our study, the adjusted relative risks of
IC-bleed associated with aspirin was estimated to be 1.38
(95% CI, 1.31–1.47), similar to the published data.
Triple therapy (TT) regimens are associated with a higher
risk of bleeding compared with anticoagulant and aspirin ther-
apy in post-acute myocardial infarction [6]. In a multicenter
randomised trial involving 2725 patients with AF who had
undergone PCI, the risk of bleeding was lower in patients
receiving DAPT compared to TT regimens without any
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significant differences in thrombotic outcomes [15]. Our
analysis found compared to monotherapies that the increased
risks of IC- or GI-bleeding associated with DAPT (aspirin and
AP) are approximately 1.5–3 times higher after adjusting for
concomitant uses of effect-modifiers (i.e. drugs that increase
the bleeding risks). Furthermore, the increased risks of IC- or
GI-bleeding associated with TT is approximately 6–16 times
higher after adjusting for concomitant uses of effect modifiers.
Also, combining anticoagulants with DAPT (i.e. turning
DAPT into TT) further increases the risks of IC- or GI-
bleeding.
The pharmaceutical collections in New Zealand cover
more than 95% of the older population, and hence the results
are generalizable to the older population. The use of a case-
crossover design mitigates confounding from unknown time-
invariant confounding variables. The advantage of using case-
crossover design is that comparisons are automatically
background-matched because they comprise the same individ-
uals, and hence mitigating the influence of unidentified or
unmeasured biological and psychosocial confounders.
Our findings are to be interpreted with caution in light of
several limitations. A case-crossover design cannot mitigate
the effect of unknown time-varying confounding variables.
We only adjusted for the concomitant use of effect-
modifying drugs as a time-varying confounding variable
when calculating the relative risks. Since this study describes
observational data from a national collection of hospital
events for bleeding, we recommend that several time-
varying confounders are to be recognised while interpreting
the risks reported in this study such as body mass index and
dietary guidance. There is a possibility of channelling bias
were doctors could prescribe antithrombotic combinations
perceived to be safer in older people, particularly in those they
consider to be at higher bleeding risk. Confounding by an
indication could potentially limit the validity of our findings.
We could not capture bleeding events that did not require
hospitalisations, and this could have underestimated the pre-
cise bleeding risk associated with antithrombotic therapy.
Finally, we could not ascertain if the dispensed medicines
were taken before the bleeding event.
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Despite the limitations, this national study provides a real-
world context and adjusted relative risks of bleeding associat-
ed with the use of antithrombotics in older people in the con-
text of multimorbidity. In our future research, we intend to
compare the risk of bleeding versus hospital admissions due
to acute cardiovascular events to inform the optimal selection
of antithrombotics in this vulnerable population.
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